Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


COVID-19 Shifts ICER Pricing Targets, Creating New Hurdles For Drug Developers

Executive Summary

With a remdesivir analysis pushing cost-recovery models and lower thresholds for cost-effectiveness, ICER's COVID-19 pricing framework will likely result in lower pricing benchmarks for drugs than the group would have issued under its typical analysis framework. Critics say this is the opposite of what should be incentivized in an emergency.

You may also be interested in...

Coronavirus Update: How Should Remdesivir Be Priced? ICER Are In Two Minds

Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.

ICER Boosts ‘Cost-Recovery’ Benchmark Price For Remdesivir To Reflect Gilead’s Planned R&D

But updated pricing model also suggests the more traditional cost effectiveness’ benchmark price for remdesivir could be lower than previously estimated to account for use of dexamethasone in reducing the underlying risk of mortality in COVID-19 patients.

Remdesivir Rivals Hit Indian Market

Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts